Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 10.28% is 10% below its 5-year average of 11.48%, around the middle of its 5-year range (1.21%–17.83%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.09% below its 12-month average of 10.94%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 10.28%.
DEBT TO ASSETS RATIO
10.28%
DEBT TO ASSETS RATIO AVG TTM
10.94%
DEBT TO ASSETS RATIO AVG 3Y
11.40%
DEBT TO ASSETS RATIO AVG 5Y
11.48%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-6.09%
CURRENT VS 3Y AVG
-9.88%
CURRENT VS 5Y AVG
-10.45%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 731 covered companies
CURRENT VS SECTOR MEDIAN
+10177.80%
vs the sector median at left
Erasca, Inc.
Market Cap
$5.08B
Debt to Assets Ratio
10.28%
TTM Avg
10.94%
3Y Avg
11.40%
5Y Avg
11.48%
Market Cap
$5.09B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.18B
Debt to Assets Ratio
0.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.21B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.24B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.90B
Debt to Assets Ratio
0.73%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.86B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.86B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Erasca, Inc. (ERAS) | $5.08B | 10.28% | 10.94% | 11.40% | 11.48% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.09B | 0.29% | N/A | N/A | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.18B | 0.39% | N/A | N/A | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.21B | 0.30% | N/A | N/A | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.24B | 0.29% | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.90B | 0.73% | N/A | N/A | N/A |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.86B | 0.00% | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.86B | 0.00% | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.34B | 0.01% | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.38B | 0.21% | N/A | N/A | N/A |
Debt/Assets
10.3%
Debt/Equity
0.12
Current Ratio
8.29
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 10.28% |
| 2026-03-31 | 9.96% |
| 2025-12-31 | 11.90% |
| 2025-09-30 | 11.49% |
| 2025-06-30 | 11.10% |
| 2025-03-31 | 10.78% |
| 2024-12-31 | 10.33% |
| 2024-09-30 | 10.01% |
| 2024-06-30 | 10.27% |
| 2024-03-31 | 17.83% |
| 2023-12-31 | 14.13% |
| 2023-09-30 | 13.53% |
| 2023-06-30 | 13.08% |
| 2023-03-31 | 12.42% |
| 2022-12-31 | 10.70% |
| 2022-09-30 | 12.20% |
| 2022-06-30 | 6.21% |
| 2022-03-31 | 6.19% |
| 2021-12-31 | 3.75% |
| 2021-09-30 | 3.88% |
| 2021-06-30 | 1.21% |
| 2021-03-31 | 1.23% |
| 2020-12-31 | 2.39% |
